Organization
Glasgow, United Kingdom
9 abstracts
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.Org: University of Leicester and Leicester University Hospitals, University of Southampton, Harry Perkins Institute of Medical Research, Perth, Australia, Liverpool, United Kingdom,
Abstract
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.Org: University College Hospital-London, NHS Foundation Trust, University College London Cancer Institute, The Christie NHS Foundation Trust, University of Leeds,
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,
Abstract
Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study.Org: Mount Vernon Cancer Center, Northwood, United Kingdom, Christie NHS Foundation Trust, Manchester, United Kingdom, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Royal Preston Hospital,
Abstract
‘real life’ biological drug tapering results in few flares of disease and significant cost savingsOrg: Rheumatology Pharmacist, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, Ukraine,
Abstract
‘ONE IS NOT ENOUGH’ - RITUXIMAB SINGLE VS DOUBLE INFUSION PROTOCOL IN TREATMENT OF ESTABLISHED RHEUMATOID ARTHRITIS – REAL LIFE EXPERIENCE OF GARTNAVEL GENERAL HOSPITAL, GLASGOW, UKOrg: Gartnavel General Hospital, Glasgow, United Kingdom,
Abstract
A MULTIDISCIPLINARY FOOT CLINICOrg: HealthQWest, Glasgow Caledonian University, Glasgow, United Kingdom, Department of Podiatry, University of Huddersfield,
Abstract
ASAS/EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF ANKYLOSING SPONDYLITISOrg: Rheumazentrum-Ruhrgebiet, St.Josefs-Krankenhaus, Herne, Germany, Maastrict, Netherlands, Mexico City, Mexico, Cordoba, Spain, San Francisco, United States,